Professional Documents
Culture Documents
Gantschnig 2013
Gantschnig 2013
net/publication/236226902
CITATIONS READS
16 346
4 authors, including:
Ingeborg Nilsson
Umeå University
59 PUBLICATIONS 836 CITATIONS
SEE PROFILE
All content following this page was uploaded by Brigitte E Gantschnig on 07 January 2016.
MeSH TERMS OBJECTIVE. We evaluated whether the Assessment of Motor and Process Skills (AMPS) measures are
activities of daily living valid for detecting differences in activities of daily living (ADL) ability among children with and without mild
disabilities.
attention deficit disorder
developmental coordination
METHOD. Retrospective data from the AMPS database were analyzed using many-facet Rasch analyses and
forced regression analyses to evaluate for significant group differences.
disorder
RESULTS. Regression analyses of data for 10,998 children ages 4–15 who met the inclusion criteria
learning disorders
revealed significant Age · Group interaction effects (B ³ 0.23, T ³ 6.20, p £ .001). Post hoc t tests revealed
sensation disorders significant group differences in ADL ability at all ages beyond age 4. ADL process ability effect sizes were
task performance and analysis moderate to large at all ages, and ADL motor ability was mostly moderate to large at ages 6 or older.
validity of results CONCLUSION. These findings support the validity of the AMPS measures when used to identify ADL
problems among children with mild disabilities.
Gantschnig, B. E., Page, J., Nilsson, I., & Fisher, A. G. (2013). Detecting differences in activities of daily living between
children with and without mild disabilities. American Journal of Occupational Therapy, 67, 319–327. http://dx.doi.
org/10.5014/ajot.2013.007013
322
Age, yr
Characteristic 4 5 6 7 8 9 10 11 12 13 14 15 Total
Gender, n (%)
Male 473 (48.7) 566 (48.8) 638 (51.9) 655 (51.9) 568 (50.4) 502 (48.6) 453 (47.7) 372 (41.6) 335 (45.8) 280 (43.3) 244 (48.3) 242 (49.8) 5,328 (48.5)
Female 499 (51.3) 595 (51.2) 592 (48.1) 607 (48.1) 558 (49.6) 530 (51.4) 496 (52.3) 522 (58.4) 397 (54.2) 367 (56.7) 261 (51.7) 244 (50.2) 5,668 (51.5)
Diagnoses, n (%)
Typical 911 (93.6) 1,041 (89.7) 1,035 (84.2) 1,035 (82.0) 924 (82.1) 875 (84.8) 833 (87.8) 811 (90.8) 661 (90.3) 594 (91.8) 454 (89.9) 440 (90.5) 9,615 (87.4)
Total mild 62 (6.4) 120 (10.3) 195 (15.8) 227 (18.0) 202 (17.9) 157 (15.2) 116 (12.2) 83 (9.2) 71 (9.7) 53 (8.2) 51 (10.1) 46 (9.5) 1,383 (12.6)
Risk 24 23 23 12 12 13 0 0 0 0 0 0 103
ADHD 0 21 54 56 66 56 51 30 29 27 24 22 440
DCD 3 13 21 25 20 18 9 6 10 6 5 2 138
LD 14 24 43 71 54 33 26 18 19 7 15 7 331
SI 16 28 37 38 23 18 16 22 4 2 1 7 212
Comorbid 5 11 17 25 27 19 14 7 9 11 6 8 159
World region, n (%)
NA 233 (24.0) 245 (21.1) 293 (23.3) 276 (21.9) 222 (19.7) 197 (19.1) 216 (22.8) 195 (21.8) 171 (23.4) 153 (23.7) 114 (22.5) 107 (22.0) 2,422 (22.0)
UK/Ireland 182 (18.8) 236 (20.3) 202 (16.4) 250 (19.8) 201 (17.8) 190 (18.4) 204 (21.5) 160 (17.9) 155 (21.2) 158 (24.4) 106 (21.0) 98 (20.2) 2,142 (19.5)
Nordic 191 (19.6) 285 (24.5) 314 (25.5) 328 (26.0) 310 (27.5) 304 (29.5) 276 (29.1) 252 (28.2) 203 (27.7) 181 (28.0) 152 (30.1) 135 (27.8) 2,931 (26.7)
SoCenAm 2 (0.2) 0 (0.0) 2 (0.2) 3 (0.2) 0 (0.0) 0 (0.0) 1 (0.1) 2 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 11 (0.1)
WEurope 64 (6.6) 64 (5.5) 65 (5.3) 85 (6.8) 72 (6.3) 68 (6.6) 48 (5.1) 43 (4.8) 35 (4.8) 23 (3.5) 21 (4.2) 19 (3.9) 605 (5.5)
ANZ 97 (9.9) 75 (6.6) 110 (8.9) 86 (6.8) 99 (8.8) 88 (8.5) 57 (6.0) 78 (8.7) 61 (8.4) 48 (7.4) 40 (7.9) 60 (12.4) 899 (8.2)
Asia 174 (17.9) 186 (16.0) 178 (14.5) 181(14.3) 144 (12.7) 123 (11.9) 105 (11.1) 142 (16.0) 82 (11.2) 76 (11.8) 60 (11.9) 58 (11.9) 1,509 (13.7)
MidEast 3 (0.3) 11 (0.9) 12 (1.0) 9 (0.7) 7 (0.6) 20 (1.9) 9 (0.9) 5 (0.5) 4 (0.5) 2 (0.3) 2 (0.4) 0 (0.0) 84 (0.8)
Africa 1 (0.1) 1 (0.1) 9 (0.7) 7 (0.5) 9 (0.8) 8 (0.8) 6 (0.6) 1 (0.1) 4 (0.5) 0 (0.0) 2 (0.4) 1 (0.2) 49 (0.4)
MEurope 20 (2.1) 51 (4.4) 38 (3.1) 26 (2.1) 49 (4.3) 29 (2.8) 20 (2.1) 9 (1.0) 11 (1.5) 5 (0.8) 5 (1.0) 1 (0.2) 264 (2.4)
SEurope 5 (0.5) 7 (0.6) 7 (0.6) 11 (0.9) 13 (1.5) 5 (0.5) 7 (0.7) 7 (0.8) 6 (0.8) 1 (0.1) 3 (0.6) 6 (1.2) 78 (0.7)
Total 972 (100) 1,161 (100) 1,230 (100) 1,262 (100) 1,126 (100) 1,032 (100) 949 (100) 894 (100) 732 (100) 647 (100) 505 (100) 486 (100) 10,996 (100.0)
Note. Typical 5 children without a diagnosis; mild 5 with mild disabilities; risk 5 children with symptoms suggestive of a mild disability; ADHD 5 attention deficit hyperactivity disorder; DCD 5 developmental coordination
disorder; LD 5 specific learning disabilities; SI 5 sensory integrative dysfunction; comorbid 5 children with two or more diagnosed mild disabilities. NA 5 North America; UK/Ireland 5 United Kingdom and Republic of
Ireland; Nordic 5 Nordic countries; SoCenAm 5 South and Central America and Caribbean; WEurope 5 Western Europe; ANZ 5 Australia and New Zealand; MidEast 5 Middle Eastern countries; MEurope 5 Middle Europe;
SEurope 5 Southern Europe.
324
Age, yr
Characteristic
and Diagnostic Group 4 5 6 7 8 9 10 11 12 13 14 15
ADL motor ability, M (SD)
Typical 1.14 (0.41) 1.29 (0.44) 1.42 (0.46) 1.56 (0.44) 1.65 (0.48) 1.79 (0.46) 1.85 (0.47) 1.96 (0.49) 2.11 (0.49) 2.18 (0.50) 2.25 (0.50) 2.30 (0.48)
Mild 1.07 (0.42) 1.16 (0.36) 1.22 (0.44) 1.34 (0.45) 1.42 (0.42) 1.50 (0.46) 1.68 (0.44) 1.60 (0.45) 1.68 (0.38) 1.81 (0.41) 1.85 (0.38) 1.87 (0.48)
Difference 0.07 0.13 0.20 0.21 0.23 0.29 0.17 0.36 0.43 0.37 0.40 0.43
t 1.36 3.63 5.57 6.94 6.91 7.30 3.84 6.46 8.77 5.15 6.80 5.87
df 971.00 1159.00 1228.00 1260.00 326.32 1030.00 947.00 893.00 730.00 645.00 503.00 484.00
p .305 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001
95% CI [2 0.03, 0.18] [0.06, 0.20] [0.13, 0.27] [0.16, 0.29] [0.17, 0.30] [0.21, 0.37] [0.09, 0.27] [0.25, 0.47] [0.32, 0.52] [0.22, 0.51] [0.28, 0.51] [0.29, 0.59]
Effect size, d 0.17 0.32 0.44 0.50 0.49 0.63 0.38 0.77 0.98 0.81 0.90 0.90
Median ADL motor ability
Typical 1.15 1.29 1.41 1.56 1.63 1.77 1.83 1.92 2.08 2.15 2.25 2.26
Mild 1.15 1.19 1.25 1.34 1.43 1.51 1.72 1.65 1.67 1.77 1.84 1.92
ADL process ability, M (SD)
Typical 0.26 (0.43) 0.45 (0.43) 0.58 (0.41) 0.71 (0.40) 0.79 (0.41) 0.93 (0.41) 0.98 (0.42) 1.07 (0.41) 1.13 (0.42) 1.20 (0.41) 1.27 (0.43) 1.30 (0.42)
Mild 0.03 (0.48) 0.13 (0.40) 0.23 (0.47) 0.31 (0.46) 0.38 (0.45) 0.48 (0.45) 0.64 (0.44) 0.56 (0.48) 0.58 (0.47) 0.70 (0.45) 0.74 (0.41) 0.77 (0.45)
Difference 0.23 0.32 0.35 0.40 0.41 0.45 0.34 0.51 0.55 0.50 0.53 0.53
t 4.03 7.68 9.76 12.98 10.32 12.48 8.19 10.63 10.53 8.53 8.34 8.09
df 971.00 1159.00 254.14 1260.00 1124.00 1030.00 947.00 893.00 730.00 645.00 503.00 484.00
p <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001
95% CI [0.12,0.34] [0.23, 0.39] [0.28, 0.42] [0.33, 0.45] 0[0.33, 0.49] [0.38, 0.52] [0.26, 0.42] [0.41, 0.60] [0.45, 0.66] 0[0.39, 0.62] [0.40, 0.65] [0.40, 0.66]
Effect size, d 0.53 0.77 0.83 0.92 0.95 1.05 0.79 1.14 1.23 1.16 1.26 1.22
Median ADL process ability
Typical 0.25 0.43 0.58 0.70 0.77 0.91 0.95 1.05 1.13 1.18 1.25 1.25
Mild 0.13 0.13 0.26 0.36 0.42 0.50 0.64 0.57 0.57 0.67 0.75 0.80
Note. The critical Bonferroni corrected value was set at a 5 .004. A d 5 0.2 is considered to be small; 0.5, moderate; 0.8, large. ADL 5 activity of daily living; CI 5 confidence interval; df 5 degrees of freedom; M 5 mean;
mild 5 mild disabilities or having symptoms suggestive of a mild disability; SD 5 standard deviation; typical 5 children without a diagnosis.
Acknowledgments
This study was funded by the Swiss National Science
Foundation (13DPD6-127161) and supported by the
Austrian, German, and Swiss Associations of Occupa-
tional Therapy. We especially thank André Meichtry and
Figure 2. Graphic representation of differences in mean ADL
Hans Stenlund for their statistical support. We also thank
process ability measures between groups with increasing age.
Note. Typical 5 children without a diagnosis; mild 5 mild disabilities or with all occupational therapists who collected data on their
symptoms suggestive of a mild disability. clients and contributed to the AMPS validation process.